Only tramiprosate, a selective anti-oligomer agent, has demonstrated potential benefit for a sub-group of APOE4 positive individuals with early AD and is currently under investigation in a phase three trial (Tolar et al., 2020). The gene discussed is APOE; the disease is Alzheimer disease.